EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer

Kang Liu, Rossella Nicoletti, Hongda Zhao, Xuan Chen, Hongwei Wu, Chi-Ho Leung, David D'Andrea, Ekaterina Laukhtina, Francesco Soria, Andrea Gallioli, Marcelo Langer Wroclawski, Daniele Castellani und 8 weitere

World Journal of Urology · 2024

DOI: 10.1007/s00345-024-05218-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Urology, 2024. Verfasst von Kang Liu und 19 weiteren Autor:innen. Beteiligte Einrichtung: S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince …. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Neoplasm Invasiveness, Adjuvants, Immunologic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UGC Research Matching Fund, General Research Fund and Early Career Scheme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the impact of ageing on survival outcomes in Bacillus Calmette–Guérin (BCG) treated non-muscle invasive bladder cancer (NMIBC) patients and its synergy with adequate BCG treatment.

Method

Patients with NMIBC who received BCG treatment from 2001 to 2020 were divided into group 1 (< = 70 years) and group 2 (> 70 years). Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan–Meier method. Multivariable Cox regression analysis was used to adjust potential confounding factors and to estimate Hazard Ratio (HR) and 95% Confidence Interval (CI). Subgroup analysis was performed according to adequate versus inadequate BCG treatment.

Results

Overall, 2602 NMIBC patients were included: 1051 (40.4%) and 1551 (59.6%) in groups 1 and 2, respectively. At median follow-up of 11.0 years, group 1 (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS as compared to group 2 (> 70 years). At subgroup analysis, patients in group 1 treated with adequate BCG showed better OS, CSS, RFS, and PFS as compared with inadequate BCG treatment in group 2, while patients in group 2 receiving adequate BCG treatment had 41% less progression than those treated with inadequate BCG from the same group.

Conclusions

Being younger (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS. Older patients (> 70 years) who received adequate BCG treatment had similar PFS as those younger with adequate BCG treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsBCG VaccineNeoplasm InvasivenessAdjuvants, ImmunologicHumansMaleAgedFemaleMiddle AgedAge FactorsTreatment OutcomeRetrospective StudiesSurvival RateAged, 80 and overAdministration, IntravesicalNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

AgeCancerFree survivalInvasive bladder cancerMuscleNonOverall survivalProgressionRecurrenceSpecific survival

Substanzen

BCG VaccineAdjuvants, Immunologic

Autor:innen und Institutionen

  • S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong.
  • Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Urothelial Cancer Working Group, European Association of Urology-Young Academic Urologists (EAU-YAU), Amsterdam, Netherlands.
  • Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, 10024, Turin, Italy.
  • Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain.

Förderung

  • UGC Research Matching Fund
  • General Research Fund and Early Career Scheme

Zitieren

APA

Liu, K., Nicoletti, R., Zhao, H., Chen, X., Wu, H., Leung, C. H., D'Andrea, D., Laukhtina, E., Soria, F., Gallioli, A., Wroclawski, M. L., Castellani, D., Gauhar, V., Rivas, J. G., Enikeev, D., Gontero, P., Shariat, S. F., Chiu, P. K., Ng, C. F., & Teoh, J. Y. (2024). Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer. World Journal of Urology. https://doi.org/10.1007/s00345-024-05218-4

Vancouver

Liu K, Nicoletti R, Zhao H, Chen X, Wu H, Leung CH, et al. Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer. World Journal of Urology. 2024. doi:10.1007/s00345-024-05218-4

BibTeX
@article{Liu2024,
  author = {Liu, Kang and Nicoletti, Rossella and Zhao, Hongda and Chen, Xuan and Wu, Hongwei and Leung, Chi-Ho and D'Andrea, David and Laukhtina, Ekaterina and Soria, Francesco and Gallioli, Andrea and Wroclawski, Marcelo Langer and Castellani, Daniele and Gauhar, Vineet and Rivas, Juan Gomez and Enikeev, Dmitry and Gontero, Paolo and Shariat, Shahrokh F and Chiu, Peter Ka-Fung and Ng, Chi-Fai and Teoh, Jeremy Yuen-Chun},
  title = {Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer},
  journal = {World Journal of Urology},
  year = {2024},
  doi = {10.1007/s00345-024-05218-4}
}
Kostenlos starten →